Formerly in the fold of Nestlé, Galderma now stands on its own two feet.
And the company now intends to list on the Swiss Stock Exchange within a month to finance its growth, as it announced on Wednesday.
Once not flourishing, the activity of this skin care specialist has experienced sustained development for four years.
Its sales increased by 8.5% last year, in a buoyant cosmetics market, and exceeded $4 billion for the first time.
The pandemic and successive confinements have reinforced consumers' desire to take care of their appearance, and in particular their skin.
In addition to the dermocosmetic brands Cetaphil or Alostil which are doing even better than the market, Galderma offers injectable products - for example it markets a competitor to Botox - and drugs intended to treat skin diseases, such as acne (Differin) or rosacea (Soolantra).
Read alsoThe boom in water-free cosmetics is solid
However, the laboratory returns…
This article is reserved for subscribers.
You have 80% left to discover.
Flash sale
€4.49/month for 12 months
I ENJOY IT
Already subscribed?
Log in